Obesity is a chronic disease that requires lifelong, integrated care—not a pill.
La Organización Mundial de la Salud ha dado un paso histórico al reconocer formalmente la obesidad como una enfermedad crónica que merece tratamiento médico sostenido, no como una falla personal. Por primera vez, la OMS respalda condicionalmente el uso de terapias GLP-1 —como semaglutida y tirzepatida— para adultos con obesidad, siempre que se combinen con apoyo conductual y cambios de estilo de vida. En un mundo donde más de mil millones de personas viven con esta condición y 3,7 millones murieron por causas relacionadas en 2024, la orientación llega cargada de urgencia, pero también de advertencias sobre equidad, seguridad a largo plazo y el riesgo de que medicamentos poderosos queden reservados solo para quienes pueden pagarlos.
- La OMS emitió su primera guía formal sobre medicamentos GLP-1 para la obesidad, marcando un giro en la política sanitaria global que podría redefinir coberturas de seguro y estándares clínicos en todo el mundo.
- La recomendación es condicional: persisten dudas sobre la seguridad a largo plazo, la durabilidad del efecto tras suspender el tratamiento y la capacidad real de los sistemas de salud para integrarlo.
- El acceso inequitativo amenaza con convertir estas terapias en un privilegio de países ricos, mientras la obesidad golpea con mayor fuerza a comunidades vulnerables con menos recursos para costear los medicamentos.
- La escasez global ha alimentado un mercado negro de productos falsificados, lo que lleva a expertos a exigir cadenas de suministro reguladas y prescripciones supervisadas para evitar daños graves a los pacientes.
- La OMS planea actualizar sus recomendaciones a medida que surjan nuevas evidencias y trabajar en 2026 con socios internacionales para priorizar a las poblaciones con mayor necesidad.
El lunes, la Organización Mundial de la Salud publicó su primera orientación formal sobre las terapias GLP-1 para el tratamiento de la obesidad, un movimiento que redefine cómo los gobiernos, aseguradoras y sistemas de salud deberán responder a una de las crisis sanitarias más extendidas del planeta. Los medicamentos en cuestión —semaglutida, tirzepatida y liraglutida— imitan una hormona natural que regula el apetito y el azúcar en sangre, produciendo una pérdida de peso significativa cuando se combinan con dieta, ejercicio y acompañamiento profesional continuo.
El director general de la OMS, Tedros Adhanom Ghebreyesus, fue enfático: la obesidad no es una falla de voluntad, sino una enfermedad crónica moldeada por la genética, el entorno y factores sociales. Con más de mil millones de personas afectadas en el mundo y 3,7 millones de muertes vinculadas a la condición solo en 2024, la urgencia es innegable. Sin intervención más agresiva, esa cifra podría duplicarse antes de 2030.
Sin embargo, el respaldo de la OMS es condicional. La organización reconoce que los datos de seguridad a largo plazo son incompletos, que aún no está claro si el efecto se mantiene al suspender el tratamiento, y que el alto costo de estos medicamentos los pone fuera del alcance de la mayoría de personas en países de ingresos bajos y medios. La investigadora Marie Spreckley, de la Universidad de Cambridge, valoró que la guía subraye que los fármacos deben integrarse en un enfoque de largo plazo, no usarse como solución aislada.
Un riesgo adicional ensombrece el panorama: el auge de la demanda ha disparado la circulación de productos falsificados. El profesor John Wilding, de la Universidad de Liverpool, advirtió que las escaseces están alimentando un mercado negro y llamó a establecer cadenas de suministro reguladas y prescripciones supervisadas. La OMS se comprometió a actualizar sus recomendaciones conforme avance la evidencia y a trabajar en 2026 para garantizar acceso prioritario a quienes más lo necesitan. La pregunta que queda abierta es si el mundo estará a la altura de esa promesa.
On Monday, the World Health Organization released its first formal guidance on a class of weight-loss medications that has reshaped how the world thinks about obesity treatment. The document represents a significant shift in global health policy—one that will likely ripple through insurance coverage decisions, clinical practice standards, and national health systems for years to come.
The guidance centers on GLP-1 therapies: semaglutida (sold as Ozempic, Wegovy, and Rybelsus), tirzepatida (Mounjaro and Zepbound), and liraglutida (Saxenda). These drugs work by mimicking a natural hormone that controls appetite, blood sugar levels, and digestion, producing substantial weight loss when paired with diet, exercise, and ongoing professional support. The WHO's endorsement matters because it legitimizes these medications as part of legitimate medical treatment rather than cosmetic intervention—a distinction with real consequences for how governments and insurers decide to fund them.
The scale of the problem the WHO is addressing is staggering. More than one billion people worldwide live with obesity, a condition linked to 3.7 million deaths in 2024. Without more aggressive intervention, that number could double by 2030. Tedros Adhanom Ghebreyesus, the WHO's director general, framed obesity not as a personal failing but as a chronic disease shaped by genetics, environment, biology, and social factors. "The obesity is an important global health problem," he said. "Our new guidelines recognize that obesity is a chronic disease that can be treated with comprehensive, lifelong care. While medications alone won't solve this global health crisis, GLP-1 therapies can help millions of people overcome obesity and reduce its harmful effects."
Yet the WHO's recommendation carries a crucial qualifier: it is conditional. The organization acknowledges significant uncertainties that prevent a full endorsement. Long-term safety data remains incomplete. Questions linger about whether weight loss persists after patients stop taking the medication. The drugs are expensive—prohibitively so for most people in low- and middle-income countries. And there is deep concern about equity: these medications risk becoming available only to wealthy populations while obesity ravages poorer communities. Marie Spreckley, an obesity researcher at Cambridge University, praised the guidance for emphasizing that medication must be combined with behavioral support and equitable access, rather than presented as a standalone fix. She noted that the document "clearly recognizes obesity as a chronic, progressive disease with relapses, requiring an integrated, long-term approach—not short-term treatment."
The WHO added GLP-1 drugs to its List of Essential Medicines in 2025 for controlling type 2 diabetes in high-risk groups. This new guidance extends that endorsement to long-term use in adults with obesity, with the exception of pregnant women. The organization emphasized that these medications must be deployed alongside broader public health measures: healthier food environments, increased physical activity, and sustained professional guidance. Obesity cannot be solved at the individual level alone, the WHO stressed. It demands coordinated action from governments and industry to reshape the systems that produce it.
But a darker concern shadows the guidance's release. As demand for these drugs has surged, so has the circulation of counterfeit and substandard products. John Wilding, a professor of medicine at the University of Liverpool, warned that shortages are driving a black market. He called for regulated supply chains, qualified prescriptions, and strict oversight to protect patients from fake medications that could cause serious harm. The WHO has committed to updating its recommendations as new evidence emerges and plans to work with international partners in 2026 to prioritize populations with the greatest need. The question now is whether the world's health systems can deliver on that promise—or whether these powerful drugs will become another tool available only to those who can afford them.
Citações Notáveis
Obesity is a chronic disease that can be treated with comprehensive, lifelong care. While medications alone won't solve this global health crisis, GLP-1 therapies can help millions of people overcome obesity and reduce its harmful effects.— Tedros Adhanom Ghebreyesus, WHO Director General
The guidance recognizes obesity as a chronic, progressive disease with relapses, requiring an integrated, long-term approach—not short-term treatment.— Marie Spreckley, obesity researcher, University of Cambridge
A Conversa do Hearth Outra perspectiva sobre a história
Why did the WHO feel it needed to issue guidance on these drugs now, rather than waiting for more long-term data?
Because the scale of obesity is accelerating faster than the data can accumulate. A billion people are living with it right now, and without intervention, that doubles by 2030. The WHO had to make a judgment call: wait for perfect information that might never come, or acknowledge what works today while being honest about what we don't yet know.
The guidance is "conditional." What does that actually mean for a patient trying to get their insurance to cover the drug?
It means the WHO is saying yes, but with caveats. Insurance companies will interpret that differently depending on their own risk tolerance and budget. Some will use it to expand coverage. Others will cite the uncertainties as reason to restrict access. That's partly why the equity problem is so acute—the conditional language gives health systems an out.
You mentioned counterfeit drugs. How bad is that problem?
Bad enough that it's becoming a public health threat in its own right. When demand outpaces supply, black markets fill the gap. People desperate to lose weight buy pills they think are semaglutida but aren't. They could be inert, or they could be dangerous. It's a consequence of scarcity meeting desperation.
The WHO says obesity isn't just about individual choices. What does that actually change about how we treat it?
Everything, theoretically. If obesity is a disease shaped by genetics, environment, and social factors, then the solution can't be just telling people to eat less and exercise more. It means governments have to redesign food systems, make healthy options accessible and affordable, create environments where physical activity is normal. That's much harder than prescribing a pill.
So these drugs won't solve the obesity crisis.
No. The WHO is clear on that. They're a tool for people who need them, but they're not the answer to a billion-person problem. The answer requires changing how we grow food, how we market it, how our cities are built. The drugs buy time and help individuals while that harder work happens—if it happens at all.